Vijaya Diagnostic Centre Limited (NSE: VIJAYA) has announced its financial results for the quarter ended 30th September 2026 and the half-year ended 30th September 2026. The company reported a strong 26.7% year-on-year revenue growth for Q2 FY27, with consolidated revenue from operations reaching Rs. 2,553.9 million compared to Rs. 2,015.6 million in the same quarter last year. Moreover, the company’s revenue for the first half of FY27 grew by 24.8% to Rs. 4,863.7 million from Rs. 3,896.1 million in the previous year.

EBITDA and Profit after Tax

The company’s EBITDA for Q2 FY27 surged by 37.8% to Rs. 1,127.5 million, up from Rs. 818.3 million in Q2 FY26. Similarly, EBITDA for the first half of FY27 increased by 36.0% to Rs. 2,112.9 million compared to Rs. 1,553.6 million in H1 FY26. Profit after tax (PAT) for Q2 FY27 rose by 37.4% to Rs. 594.7 million, while for H1 FY27, PAT grew by 37.5% to Rs. 1,125.7 million.

Operational Highlights

The company’s operational highlights include a 16.5% increase in total tests for Q2 FY27 and a 16.5% rise in total footfall. Additionally, the average realization per test increased by 8.8% to Rs. 513 in Q2 FY27. For the first half of FY27, the total tests grew by 13.7% and total footfall increased by 13.7%.

Commenting on the business outlook, Ms. Suprita Reddy, MD & CEO, said, ‘We have sustained our strong growth momentum during Q2 FY27, delivering 26.7% year-on-year revenue growth, supported by 16.5% volume growth.’ The company plans to commission another 3 hubs and 7 spokes in H2 FY27, followed by 3 additional hubs in Q1 FY28, further strengthening its network and expanding its presence across key markets.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Vijaya Diagnostic Centre Limited

Vijaya Diagnostic Centre Limited belongs to the Healthcare › Diagnostics & Research sector. Here’s a quick read on where the business and the stock stand today.

Vijaya posts a 3.0% three-month gain, but softens in the last few weeks. Premium net margins of 21.9% demonstrate strong cost discipline and a wide competitive moat. Revenue grows at 21.0% and profits at 26.9% CAGR. Both numbers are exceptional. The stock gives back 3.9% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 21.0% and profits at 26.9%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Vijaya Diagnostic Centre Limited.

Metropolis Healthcare Limited (NSE: METROPOLIS) announced its unaudited consolidated financial results for the quarter ended 30th September 2026, marking a strong performance for Q2 FY27. The company reported a revenue increase of 16% year-over-year to ₹497 crore, while Profit After Tax (PAT) surged by 43% to ₹7.5 crore.

Financial & Operational Highlights

The financial results showcased a robust performance across various metrics. The EBITDA rose 24% year-over-year to ₹13.5 crore, and the EBITDA margin expanded by 180 basis points to 27.2%. The PAT margin also improved by 290 basis points to 15.2%.

Revenue Growth and Market Expansion

Patient volume grew by 10% year-over-year to 4.1 million, and test volume increased by 11% to 8.7 million. B2C revenue grew 17% to ₹289 crore, driven by lifecycle-led customer engagement and strong brand recall. B2B revenue rose 15% to ₹208 crore, fueled by new client additions and increased uptake of specialized tests. TruHealth revenue grew 20% to ₹86 crore, and Specialty revenue rose 20% to ₹198 crore, led by advanced genomic testing and cancer testing growth.

Looking Ahead

Metropolis Healthcare Limited plans to extend its presence in Tier II and III towns, scale its wellness and specialty portfolio, and broaden engagement with doctors and hospitals. The company aims to sustain this growth through disciplined execution and greater productivity.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Metropolis Healthcare Limited

Metropolis Healthcare Limited belongs to the Healthcare › Diagnostics & Research sector. Here’s a quick read on where the business and the stock stand today.

Metropolis holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG stands at 57.60 — severely stretched. Any earnings miss could trigger a sharp de-rating. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock trades at 77% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 2.5% in three months on 11.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Metropolis Healthcare Limited.

Nephrocare Health Services Limited, Asia’s largest dialysis network under the brand “NephroPlus,” announced its Financial Results for the second quarter and half year ended 30th September 2026. The company reported a robust performance with H1 FY27 revenue of ₹ 585.2 crore, an increase of 23.6% YoY, driven by treatments up 12.6% YoY to 21.01 lakh and guests up 9.6% YoY to 38,814, alongside a 9.7% YoY increase in revenue per treatment to ₹2,785.

Financial Highlights

The company’s H1 FY27 Adjusted EBITDA* stood at ₹ 134.4 crore, an increase of 15.3% YoY. The Adjusted PAT# grew 34.7% YoY to ₹76.1 crore, with a margin up 107 bps to 13.0%. The network expanded to 570 clinics across 6 countries with entry into Kazakhstan, making international business ~47% of revenue.

Operational Insights

Commenting on the Q2 & H1 FY27 results, Mr. Vikram Vuppala, Chairman & MD, said, “Dialysis market across the World continues to grow due to the increasing burden of Diabetes and Hypertension as well as improving access due to various interventions. NephroPlus continues to grow healthily in India and international markets and expect margins to remain in healthy range. We are excited to open NephroPlus in Kazakhstan, which will be our 6th market. The two clinics we acquired are a good starting point for us to better understand the local market nuances before we start scaling this network in Kazakhstan.”

As we enter new markets, margins and returns will move during the ramp-up. That’s the nature of building something new. But they will stay healthy, because our goal is clear: a scalable global dialysis platform built for the long term,” added Mr. Prashant Goenka, Chief Financial Officer.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Nephrocare Health Services Limited

Nephrocare Health Services Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Nephrocare moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 8.1% leave limited room for error — any demand softness or cost spike hits the bottom line hard. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. RSI stands at 30, well into oversold territory. Yet sellers still dominated on 18 of recent sessions versus 12 for buyers, so the pressure has not fully lifted. Revenue grows at 33.9% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Nephrocare Health Services Limited.